ARYx Therapeutics Inc (NASDAQ:ARYX), a biopharmaceutical company,
announced today that a conference call to discuss second quarter 2009
results and to provide a general business update will be held on
Thursday, August 13, 2009 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 877-440-5784
Dial In (International): 719-325-4856
Passcode (if requested): 4948763
Preregistration is not required. This call is also being Webcast and
will be available live via the Internet by accessing the ARYx
Therapeutics’ Website at www.aryx.com.
Replays of the call will be available through August 31, 2009 at ARYx’s
Website.
About ARYx Therapeutics, Inc.
ARYx Therapeutics is a biopharmaceutical company focused on developing a
portfolio of internally discovered products designed to eliminate known
safety issues associated with well-established, commercially successful
drugs. ARYx uses its RetroMetabolic Drug Design technology to design
structurally unique molecules that retain the efficacy of these original
drugs but are metabolized through a potentially safer pathway to avoid
specific adverse side effects associated with these compounds. ARYx
currently has four products in clinical development: an oral
anti-arrhythmic agent for the treatment of atrial fibrillation,
budiodarone (previously named ATI-2042); an oral anticoagulant agent for
patients at risk for the formation of dangerous blood clots, tecarfarin
(previously named ATI-5923); a prokinetic agent for the treatment of
various gastrointestinal disorders, ATI-7505; and, an agent for the
treatment of schizophrenia and other psychiatric disorders, ATI-9242.
Please visit our Website at www.aryx.com
for additional information.
ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 x 211
